Does Health Net Cover Eliquis? A Woman's Guide to Coverage, Costs, and Alternatives

What Is Eliquis and Why Are Women Prescribed It?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that blocks Factor Xa to prevent blood clots from forming or growing. Women are prescribed it for several reasons that are, in many cases, directly tied to female physiology and hormonal status.

The main indications approved by the FDA include:

• Nonvalvular atrial fibrillation (to reduce stroke risk)
• Deep vein thrombosis (DVT) treatment and prevention of recurrence
• Pulmonary embolism (PE) treatment
• Prevention of DVT after hip or knee replacement surgery

Apixaban received FDA approval for atrial fibrillation in 2012, and its use has expanded steadily since then.

Why Women's Clot Risk Is Different

Clot risk in women is shaped by hormones in ways that don't apply to men. Estrogen-containing contraceptives increase venous thromboembolism (VTE) risk by roughly three to four times compared to non-users, according to data published in the BMJ. Menopausal hormone therapy, particularly oral formulations containing conjugated equine estrogen, carries a similar elevation in risk. The Women's Health Initiative trial found a 2.1-fold increase in VTE risk among women using oral combined hormone therapy.

Pregnancy and the postpartum period are additional windows of sharply elevated risk. A woman's clotting factor profile shifts dramatically during gestation, and the six-week postpartum window carries the highest absolute VTE risk of any period in a woman's reproductive life.

Female-Specific Conditions That Lead to Eliquis Prescriptions

Several conditions common in women intersect directly with clot risk or atrial fibrillation:

• PCOS: Insulin resistance and elevated androgen levels in polycystic ovary syndrome are associated with a prothrombotic state. A 2020 meta-analysis in Fertility and Sterility confirmed that women with PCOS have approximately a 1.9-fold higher VTE risk than controls.
• Endometriosis: Surgical management increases postoperative clot risk.
• Atrial fibrillation in menopause: The prevalence of AFib rises after menopause as estrogen's cardioprotective effects diminish, making anticoagulation a more frequent consideration for women in their 50s and 60s.

Does Health Net Actually Cover Eliquis?

Health Net covers Eliquis on its commercial, Covered California, and Medi-Cal managed care formularies, but coverage terms differ meaningfully across plan types.

Tier Placement and What That Means for Your Wallet

Across Health Net's major plan categories, Eliquis is most commonly placed at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Your cost-sharing at each tier depends on whether you've met your deductible:

| Plan Type | Typical Tier | Estimated Copay / Coinsurance (post-deductible) | |---|---|---| | Health Net Commercial HMO | Tier 3 | $47-$80 per 30-day fill | | Health Net Commercial PPO | Tier 3-4 | $80-$150 per 30-day fill | | Health Net Covered California | Tier 3 | $75-$110 per 30-day fill | | Health Net Medi-Cal (managed care) | Preferred | Low or $0 copay if criteria met |

These figures are estimates based on publicly available formulary documents as of early 2025. Your actual cost depends on your specific plan document, which you can verify at the Health Net formulary search tool or your plan's Evidence of Coverage.

Prior Authorization: The Biggest Barrier

Most Health Net plans require prior authorization (PA) before they will cover Eliquis. PA criteria typically include:

1. A documented diagnosis of AFib, DVT, PE, or post-surgical VTE prophylaxis
2. A statement from your prescriber that a trial of warfarin is contraindicated or that Eliquis is clinically preferred
3. Relevant lab values or imaging (for DVT/PE, a positive Doppler ultrasound or CT pulmonary angiogram report)

If you are denied at the PA stage, you have the right to appeal. The Affordable Care Act requires all marketplace plans to offer an internal appeal followed by an independent external review.

Step Therapy: Will They Ask You to Try Something Else First?

Some Health Net plans include step therapy requirements, meaning they may want documentation that you have tried (or have a clinical reason to avoid) warfarin before they approve Eliquis. In California, the Step Therapy law (California Health and Safety Code Section 1367.206) limits how insurers may apply step therapy for anticoagulants when a prescriber provides clinical justification. Ask your prescriber to include that justification in the PA request letter.

What Eliquis Costs Without Coverage and How to Reduce It

No approved generic apixaban existed in the United States as of January 2025. The brand-name retail price sits at roughly $550 to $600 for a 30-day supply at standard pharmacies. This is not a cost most women can sustain out-of-pocket indefinitely.

Manufacturer Savings Programs

Bristol-Myers Squibb and Pfizer co-market Eliquis and offer two assistance pathways:

• Eliquis 360 Support Copay Card: Commercially insured patients may pay as little as $10 per month. Eligibility details are on the official Eliquis savings page. Government-insured patients (Medicare, Medicaid) are not eligible.
• BMS Patient Assistance Foundation: Uninsured or underinsured patients below a certain income threshold may receive Eliquis at no cost. Applications are submitted through your prescriber's office.

GoodRx and Pharmacy Discount Programs

GoodRx coupons can bring the cash price to approximately $430 to $490 at some pharmacies, which is a partial reduction but still steep for long-term use. Mark Cuban's Cost Plus Drugs does not carry brand Eliquis as of 2025 because no generic exists.

When Health Net Denies Coverage: Your Step-by-Step Response

Women navigating a coverage denial for Eliquis face a process that most clinicians underexplain. Here is a concrete sequence:

1. Get the denial in writing. Health Net must provide a written Explanation of Benefits (EOB) stating the reason for denial, usually within 15 days for non-urgent cases.
2. Ask your prescriber for a peer-to-peer review. Your doctor or NP can call Health Net's medical director directly to argue clinical necessity. This step resolves a significant number of PA denials before a formal appeal is filed.
3. File the internal appeal. You have 180 days from the denial date under ACA rules. Submit the appeal with clinical notes, imaging reports, and a letter of medical necessity.
4. Request an expedited appeal if clinically urgent. For acute DVT or PE, you are entitled to a decision within 72 hours.
5. File for external independent review if the internal appeal fails. In California, the Department of Managed Health Care (DMHC) manages this process and can be reached through the DMHC Help Center.
6. Use the BMS copay card or patient assistance in the interim so you do not interrupt therapy while the appeal is pending.

Eliquis Across Women's Life Stages

How Eliquis fits into your care changes substantially depending on where you are in your reproductive and hormonal life.

Reproductive Years (Ages 18-40)

Women of reproductive age who are prescribed Eliquis most commonly receive it after a DVT or PE, sometimes triggered by estrogen-containing contraceptives. The standard treatment course is at least three months, after which the prescriber reassesses clot recurrence risk.

A critical point: if you are on Eliquis for ongoing VTE prevention or AFib, you must use effective non-estrogen contraception. Intrauterine devices (hormonal or copper), progestin-only pills, or barrier methods are all compatible. Estrogen-containing methods (combined oral contraceptives, the patch, the ring) add clot risk on top of the anticoagulation indication, creating a pharmacologically conflicted situation.

ACOG recommends that women with a personal history of VTE avoid estrogen-containing contraception entirely.

Trying to Conceive

If you are planning a pregnancy while taking Eliquis, transition planning is essential and time-sensitive. Apixaban is teratogenic in animal models and carries no adequate human pregnancy data, meaning it must be switched to low-molecular-weight heparin (LMWH) before conception, not at the positive pregnancy test.

Talk to your prescriber at least three months before you plan to conceive so the transition to LMWH (typically enoxaparin) can be made safely.

Pregnancy and Postpartum

Eliquis is contraindicated throughout pregnancy. Apixaban crosses the placenta. Animal reproductive studies showed increased bleeding complications in fetuses. The FDA label for apixaban states that all anticoagulants, including apixaban, increase the risk of hemorrhage during pregnancy and delivery. The drug should not be used in pregnant women.

The anticoagulant of choice during pregnancy for women who need one is LMWH (enoxaparin or dalteparin), which does not cross the placenta. Warfarin is contraindicated in the first trimester due to embryopathy and is used only under specific circumstances in the second trimester.

Postpartum and lactation: Eliquis is not recommended during breastfeeding. It is not known whether apixaban is excreted in human breast milk. Animal studies have detected it in milk. Given the potential for serious adverse reactions in a nursing infant, including bleeding, the conservative clinical recommendation is to avoid it during breastfeeding. If anticoagulation is required postpartum, discuss LMWH or warfarin with your provider, both of which have a longer safety record in lactating women.

Perimenopause

Perimenopause marks a period of rising AFib risk as estrogen levels fluctuate and then fall. Atrial fibrillation prevalence in women rises steeply after age 55, with the Framingham Heart Study data showing that lifetime AFib risk for a 55-year-old woman is approximately 26%. Women in perimenopause who are newly diagnosed with AFib are likely candidates for anticoagulation, and Eliquis is among the preferred DOACs because its twice-daily dosing provides more consistent Factor Xa coverage than once-daily alternatives.

Women in this life stage are also frequently on menopausal hormone therapy. Oral estrogen therapy raises VTE risk; transdermal estradiol does not appear to carry the same risk and is generally preferred when a woman has any thrombotic risk factor. The ESTHER study confirmed that transdermal estradiol carried no significant increase in VTE risk compared to non-users, a finding relevant to prescribing decisions for women who need both hormone therapy and anticoagulation.

Post-Menopause

Post-menopausal women on Eliquis for AFib or recurrent VTE face the longest treatment horizons. Bone health becomes a consideration: anticoagulation with warfarin is associated with reduced bone mineral density, while data on DOACs like apixaban suggest a more neutral or even slightly favorable effect on bone. A 2021 analysis in JAMA Network Open found that DOAC users had a lower risk of hip fracture compared to warfarin users, which is clinically meaningful for post-menopausal women already at elevated osteoporosis risk.

Who Eliquis Is Right For and Who It May Not Be

This section is not a substitute for a conversation with your clinician, but it gives you a framework for that conversation.

Women Who Are Likely Good Candidates

• Diagnosed with nonvalvular AFib and a CHA2DS2-VASc score of 2 or higher
• Recovering from an acute DVT or PE
• Post-surgical VTE prophylaxis after hip or knee replacement
• Warfarin-intolerant due to dietary restrictions, labile INR, or drug interactions
• Women who travel frequently (warfarin monitoring is logistically difficult)

Women Who May Need a Different Approach

• Currently pregnant or planning conception within 3 months
• Breastfeeding a newborn
• Severe renal impairment (creatinine clearance <15 mL/min; use with extreme caution and specialist guidance)
• Active pathological bleeding
• Mechanical heart valve (DOACs are contraindicated; warfarin is required)
• Women with antiphospholipid syndrome (APS): a 2019 trial in the New England Journal of Medicine found that rivaroxaban, a related DOAC, was inferior to warfarin in triple-positive APS patients; similar concern applies to apixaban

The Evidence Gap for Women

Women have been underrepresented in many of the key DOAC trials. In the ARISTOTLE trial, which established Eliquis's non-inferiority to warfarin in AFib, women comprised only 35% of the 18,201 enrolled participants. Subgroup analyses suggest similar efficacy and bleeding profiles in women, but a dedicated sex-stratified analysis of sufficient power has not been published as a standalone trial. This is a genuine evidence gap. Dosing recommendations and safety data are extrapolated from mixed-sex populations, not derived exclusively from female participants.

Sex-Specific Pharmacology: How Apixaban Behaves Differently in Women

Apixaban's pharmacokinetics show modest sex differences that are worth knowing.

Women tend to have lower body weight on average than men, and body weight influences apixaban exposure. The dose-reduction criteria for Eliquis in AFib include at least two of three factors: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. Because women more often meet the weight criterion (<60 kg), they are more frequently eligible for the reduced 2.5 mg twice-daily dose. The FDA label specifies that the dose reduction applies when at least two of three criteria are present.

Renal function also differs between sexes. Women have lower baseline creatinine values, meaning a "normal-looking" creatinine of 1.0 mg/dL in an older woman may reflect meaningfully reduced kidney function when corrected for body surface area. Use the CKD-EPI equation rather than raw creatinine to assess renal clearance before and during apixaban therapy.

Drug interactions with hormonal medications deserve attention. No direct pharmacokinetic interaction between apixaban and estradiol or progesterone has been identified at standard doses. However, medications used in women's health that are CYP3A4 or P-glycoprotein inducers or inhibitors can alter apixaban levels. Fluconazole (used for recurrent yeast infections) inhibits CYP3A4 and may raise apixaban exposure modestly; rifampin (occasionally used for certain infections) sharply reduces apixaban levels.

Talking to Your Health Net Plan: Practical Scripts

Getting Eliquis covered sometimes requires persistence and the right language. Here are specific phrases that work in prior authorization appeals:

For AFib: "Patient has documented nonvalvular atrial fibrillation with a CHA2DS2-VASc score of [X], meeting the threshold for anticoagulation per 2023 ACC/AHA guidelines. Apixaban is preferred over warfarin due to [labile INR / dietary restrictions / patient history of warfarin intolerance / patient preference after informed discussion]."

For DVT/PE: "Patient sustained a provoked/unprovoked DVT/PE confirmed by [imaging modality and date]. Current standard of care per [ACOG Practice Bulletin / ASH 2020 guidelines] supports DOAC therapy. Apixaban is the prescribed agent."

As WomanRx clinician reviewer Elena Vasquez, MD, puts it: "Women dealing with a Health Net prior authorization denial for Eliquis should ask their prescriber explicitly to document the sex-specific risk factors, such as prior OCP-related DVT, postpartum thrombosis, or PCOS-related hypercoagulability, because these details strengthen the case that this particular patient, not just this diagnosis, needs this drug."

Monitoring and Follow-Up for Women on Eliquis

Unlike warfarin, apixaban requires no routine INR monitoring. But that does not mean no monitoring.

For women on long-term apixaban, your provider should check:

• Renal function: At least annually, more often if you have CKD or are over 75. Dose adjustments may be needed if creatinine clearance changes.
• Hepatic function: Apixaban is partly metabolized by the liver. Significant hepatic impairment is a contraindication.
• Bleeding symptoms: Heavy menstrual bleeding (HMB) is the most common bleeding complaint women report on DOACs. A 2021 study in Research and Practice in Thrombosis and Haemostasis found that 68% of premenopausal women on DOACs reported an increase in menstrual blood loss. If your periods become significantly heavier, this is a clinically reportable symptom, not an expected side effect to tolerate silently.
• Blood pressure: Hypertension raises AFib risk and also increases hemorrhagic stroke risk in anticoagulated patients.
• Bone mineral density: Particularly relevant in post-menopausal women; discuss screening with your provider if you have not had a DEXA scan.